Becton Dickinson and Co (BDX) - Medical Equipment - Deals and Alliances Profile

Region:North America

Author(s):

Product Code:GDME511D

Download Sample Report download
Buy the Full ReportStarting from $250
Published on

October 2018

Total pages

208

Table of Content

Download Sample Report download
Buy the Full ReportStarting from $250

About the Report

About the Report

Summary

Becton Dickinson and Co (BD) is a medical technology company that manufactures and sells medical devices, reagents and instruments. Its major products include syringes and pen needles; intravenous catheters; infusion pumps and disposables; automated medication dispensing and supply management systems; prefillable drug delivery systems; respiratory ventilation and diagnostics equipment and consumables; products for the safe collection and transport of diagnostics specimens; instruments and reagent systems to detect a broad range of infectious diseases, healthcare-associated infections and cancers and various clinical research tools. BD offers its products to life science researchers, healthcare institutions, clinical laboratories, pharmaceutical industry and general public. The company sells its products in the Americas, Europe, the Middle East, Africa and Asia-Pacific. BD is headquartered in New Jersey, the US.

Becton Dickinson and Co (BDX)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Products

Products

Becton Dickinson and Co, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Table of Contents

Table of Contents

Table of Contents

Table of Contents 3

List of Tables 7

List of Figures 9

Becton Dickinson and Co, Medical Equipment, Deals By Year, 2012 to YTD 2018 10

Becton Dickinson and Co, Medical Equipment Deals By Type, 2012 to YTD 2018 11

Becton Dickinson and Co, Medical Equipment, Deals By Region, 2012 to YTD 2018 12

Becton Dickinson and Co, Medical Equipment, Deals By Market, 2012 to YTD 2018 13

Becton Dickinson and Co, Medical Equipment, Deals Summary, 2012 to YTD 2018 15

Becton Dickinson and Co, Medical Equipment, Deal Details 21

Asset Purchase 21

Becton, Dickinson Rumored to Sell Respiratory Devices Business 21

C. R. Bard Acquires Technology from 3DT Holdings 22

Venture Financing 23

MeMed Raises USD70 Million in Financing Round 23

Medaware Raises USD8 Million in Series A Financing 25

TVA Medical Raises USD15 Million in Series C Financing 26

Embo Medical Raises USD3.7 Million in Seed Funding 27

Vascular Pathways Secures USD5 Million from Square 1 Bank 28

Vascular Pathways Raises USD5.5 Million in Venture Financing 29

TVA Medical Raises USD 9.5 Million In Series B Venture Financing 30

GenCell Biosystems Raises USD 3.5 Million In Seed Financing Round 31

Private Equity 32

Apax Partners to Acquire Remaining Minority Stake in Vyaire Medical for USD435 Million 32

UK Medical's Managment Acquires Company from Becton Dickinson 33

CareFusion Reportedly Elicits Acquisition Interest From Private Equity Firms 34

Partnerships 35

Roche Enters into Licensing Agreement with Becton Dickinson 35

Vancive Medical Enters Into Licensing Agreement With CareFusion For Antimicrobial Dressing 36

Asuragen Enters Into Licensing Agreement With Becton, Dickinson 37

SDIX Enters Into Licensing Agreement With BD Diagnostic 38

Noble Enters into Agreement with Becton Dickinson 39

Becton Dickinson and UniteOR Enter into Agreement 40

Becton, Dickinson Enters into Research Agreement with Juvenile Diabetes Research Foundation 41

Becton, Dickinson Forms Joint Venture with Apax Partners 42

Becton Dickinson and Singapore Immunology Network Enter into Research Agreement 43

Becton, Dickinson Enters into Distribution Agreement with Check-Points 44

Becton, Dickinson Enters into Co-Marketing Agreement with Sight Diagnostics 45

CareFusion Enters into Distribution Agreement with ResMed 46

CareFusion Enters into Distribution Agreement with AAM Healthcare 47

Edwards Lifesciences Enters into Agreement with CareFusion 48

Seegene Enters into Co-Development Agreement with BD Life Sciences 49

Becton, Dickinson Enters into Agreement with FlowJo 50

BD Life Sciences Enters into Co-Marketing with Cellular Research 51

Selah Genomics, Greenville Health, DecisionQ and Becton Dickinson Enter into Agreement 52

CareFusion Enters into Distribution Agreement with Breas Medical for Vivo Line of Ventilators 53

Boston Scientific Enters into Distribution Agreement with C. R. Bard for Lutonix DCB 54

Becton, Dickinson Enters into Agreement with Aethon to Develop Integrated Medication Management Solution 55

GenCell Biosystems To Enter Into Agreement With Fiocruz, Institute Of Molecular Biology Of Parana And Immunobiological Technology Institute To Develop Clinical Screening Systems 56

Terumo Enters Into Distribution Agreement With CareFusion For SurFlash Catheters In US 57

Becton, Dickinson Enters Into Collaboration Agreement With CME Medical For Saf-T-Intima Safety Integrated IV Catheter System 58

Juvenile Diabetes Research Extends Co-Development Agreement With Becton, Dickinson For Infusion And Glucose Monitoring Device 59

BD Diagnostics Amends Agreement With Bruker For BD Bruker Maldi Biotyper System 60

CytoVas And BD Biosciences Enter Into Co-Development Agreement For Vascular Health Diagnostics 61

Intelligent Hospital Systems Enters Into Technology Integration Agreement With Cato Software Solutions 62

BD Diagnostic Systems Enters Into Agreement With Lab21 To Develop New Oncology Assays 63

University of Limerick Enters Into Co-Development Agreement With GenCell 64

Epistem Enters Into Distribution Agreement With Becton Dickinson For Mycobacterium TB Test 65

Juvenile Diabetes Research Foundation Extends Co-Development Agreement With Becton, Dickinson 66

CareFusion Extends Distribution Agreement With Fisher & Paykel Healthcare 67

Becton, Dickinson Enters into Licensing Agreement with DiabetOmics 68

Equity Offering 69

Becton Dickinson Raises USD2.47 Billion in Public Offering of Depositary Shares 69

Becton Dickinson Raises USD2.47 Billion in Public Offering of Shares 71

Becton, Dickinson Files Registration Statement For Public Offering Of Securities 73

Debt Offering 74

Becton, Dickinson Raises USD374 Million in Public offering of 0.368% Notes Due 2019 74

Becton Dickinson Raises USD337.4 Million in Public Offering of 3.02% Notes Due 2025 75

Becton Dickinson Raises USD354.4 Million in Public Offering of 1.401% Notes Due 2023 76

Becton, Dickinson Raises USD 826.05 Million in Public Offering of 0.368% Notes Due 2019 77

Becton, Dickinson Raises USD2.4 Billion in Public Offering of 3.7% Notes Due 2027 78

Becton, Dickinson to Raise USD1 Billion in Public Offering of 2.404% Notes Due 2020 79

Becton, Dickinson to Raise USD1.75 Billion in Public Offering of 3.363% Notes Due 2024 80

Becton, Dickinson to Raise USD725 Million in Public Offering of 2.133% Notes Due 2019 81

Becton, Dickinson to Raise USD1.5 Billion in Public Offering of 4.669% Notes Due 2047 82

Becton, Dickinson to Raise USD500 Million in Public Offering of Floating Rate Notes Due 2022 83

Becton, Dickinson to Raise USD1.8 Billion in Public Offering of 2.894% Notes Due 2022 84

Becton Dickinson Prices Public Offering of 1% Notes Due 2022 for USD500 Million 85

Becton Dickinson Prices Public Offering of 1.9% Notes Due 2026 for USD500 Million 87

C. R. Bard Raises USD500 Million in Public Offering of 3% Notes Due 2026 89

Becton, Dickinson Raises USD1.2 Billion in Public Offering of 4.685% Notes Due 2044 90

Becton, Dickinson Raises USD1.75 Billion in Public Offering of 3.734% Notes Due 2024 92

Becton, Dickinson Raises USD750 Million in Public Offering of Floating Rate Notes Due 2016 94

Becton, Dickinson Raises USD1.25 Billion in Public Offering of 1.8% Notes Due 2017 96

Becton, Dickinson Raises USD1.25 Billion in Public Offering of 2.675% Notes Due 2019 98

CareFusion Raises USD300 Million in Public Offering of Notes Due 2044 100

CareFusion Raises USD300 Million in Private Placement of Notes Due 2017 101

CareFusion Raises USD400 Million in Public Offering of Notes Due 2024 103

CareFusion Completes Private Placement Of Notes Due 2023 For USD 300 Million 104

C. R. Bard Raises USD500 Million in Public Offering of 1.375% Notes Due 2018 105

Asset Transactions 106

Thermo Fisher Scientific to Acquire Advanced Bioprocessing Business from Becton, Dickinson and Company 106

Merit Medical Acquires Product Line from Becton, Dickinson for USD100 Million 107

Stryker Acquires Vertebral Augmentation Solutions Business from Becton, Dickinson 109

Fresenius Kabi USA Acquires US Pharma Plant and Ready to Administer Drugs from Becton, Dickinson 110

Becton, Dickinson May Divest Surgical Instruments Unit 111

Corning Completes Acquisition of Majority Stake In Discovery Labware Unit Of Becton, Dickinson For USD 730 Million 112

Natus Medical Completes Acquisition Of Nicolet Business From CareFusion For USD 58 Million 114

Acquisition 116

Becton Dickinson Acquires TVA Medical 116

Vyaire Medical Acquires Acutronic Medical Systems 117

Becton, Dickinson Acquires C. R. Bard for USD24 Billion 118

Becton, Dickinson Acquires Remaining 60% Stake in Caesarea Medical Electronics 120

C. R. Bard Acquires Liberator Medical for USD181 Million 121

C. R. Bard Acquires Embo Medical 123

C. R. Bard Acquires 50% Joint Venture Interest in Medicon from Kobayashi Pharma 124

Becton, Dickinson Acquires Cellular Research 125

C. R. Bard Acquires Vascular Pathways from MVM Life Science Partners 126

C. R. Bard Acquires Vascular Pathways Europe from MVM Life Science Partners 127

Becton, Dickinson Acquires CareFusion for USD12.2 Billion 128

BD Acquires CRISI Medical Systems 130

Becton, Dickinson Acquires GenCell Biosystems 131

Becton, Dickinson Acquires Alverix From Safeguard Scientifics And New Venture Partners For USD 40 Million 132

CareFusion Completes Partial Acquisition Of Vital Signs From GE Healthcare For USD 470 Million 134

C. R. Bard Completes Acquisition Of Rochester Medical For USD 262 Million 135

Boston Scientific Completes Acquisition of Bard Electrophysiology From C. R. Bard For USD 275 Million 136

CareFusion Acquires Stake In Sendal From GED Capital 138

Davol Completes Acquisition Of Medafor 139

C. R. Bard Acquires Loma Vista Medical 140

Becton, Dickinson Acquires Cato Software Solutions, Maker Of Medical Software Solutions 141

Becton, Dickinson Completes Acquisition Of Safety Syringes, Developer Of Anti-Needlestick Devices 142

Carefusion Completes Acquisition Of Intermed Equipamento Medico Hospitalar, Respiratory Device Company 143

C. R. Bard Acquires Neomend, Developer Of Wound Healing Products, For Up To USD 165 Million 144

Becton, Dickinson Acquires Sirigen, Developer Of Polymer Dyes 146

CareFusion Acquires UK Medical, Distributor Of Medical Products 148

Becton, Dickinson Acquires KIESTRA, Provider Of Lab Automation Solutions 149

Becton Dickinson and Co - Key Competitors 150

Becton Dickinson and Co - Key Employees 151

Becton Dickinson and Co - Locations And Subsidiaries 153

Head Office 153

Other Locations & Subsidiaries 153

Recent Developments 160

Strategy And Business Planning 160

Oct 25, 2017: BD Breaks Ground on $60 Million Expansion of Nebraska Manufacturing Facility 160

Jun 13, 2017: FlowJo and BD to Provide Cloud Platform for Real-Time Single-Cell Marketing Collaboration 161

May 09, 2017: BD and UniteOR to develop new surgical tray management solution 162

Financial Announcements 163

Aug 02, 2018: BD announces results for 2018 third fiscal quarter; raises fiscal 2018 revenue guidance 163

May 03, 2018: BD Announces Results For 2018 Second Fiscal Quarter; Raises Fiscal 2018 Guidance 165

Feb 06, 2018: BD Announces Results For 2018 First Fiscal Quarter; Provides Fiscal 2018 Guidance Updated For Inclusion Of Bard 167

Aug 03, 2017: BD Announces Results For 2017 Third Fiscal Quarter 169

May 02, 2017: BD Announces Results For 2017 Second Fiscal Quarter 171

Feb 02, 2017: BD Announces Results For 2017 First Fiscal Quarter 173

Corporate Communications 175

Aug 16, 2018: BD elects Jeffrey Henderson to board of directors 175

Aug 01, 2018: BD appoints Simon Campion to Interventional Segment President 176

Jun 01, 2018: BD Appoints John DeFord As Chief Technology Officer 177

Apr 27, 2018: BD Names Three Executives to Segment Leadership Roles 178

Apr 23, 2017: BD Announces Appointment Of Tom Polen As President 179

Legal and Regulatory 180

Jan 11, 2018: FDA warns Becton Dickinson & Company of significant violations of the law as part of ongoing investigation into lead testing issues 180

Oct 31, 2017: Eastern District Court Denies Motion to Reconsider Becton, Dickinson and Co. Judgment 181

Sep 15, 2017: Retractable Technologies Files Motions in Connection with Becton, Dickinson Judgment 182

Aug 18, 2017: District Court Issues Final Judgment - Retractable Technologies v. Becton, Dickinson 183

Mar 21, 2017: Retractable Technologies Announces Litigation Updates 184

Government and Public Interest 185

Jun 27, 2018: BD, Heart to Heart International and the NAFC Announce 2018 Grantees for a Multi-Year Point of Care Testing Initiative to Improve Patient Outcomes 185

Mar 22, 2018: Statement from FDA's Donald St. Pierre on findings from ongoing investigation into lead testing issues 186

Dec 11, 2017: BD Establishes Product Security Partnership Program to Enhance Cybersecurity of Medical Technology 187

Jun 06, 2017: BD Releases 2016 Sustainability Report 189

Mar 28, 2017: BD Announces Success of Helping Build Healthy Communities Program, Launches New Effort Focused on Medication Therapy Management 190

Product News 191

Jul 26, 2018: BD Drives the Future of Immunology Research with Expanded Offerings for Simultaneous RNA and Protein Expression Analysis 191

Jun 20, 2018: BD to Demonstrate Expanded Vascular Access Offerings from Insertion to Removal during the 5th World Congress on Vascular Access (WoCoVA) 192

Mar 27, 2018: BD Field Safety Notice on Vacutainer Citrate Plus Blood Collection Tubes 193

Mar 05, 2018: BD to Demonstrate Enhanced Integration Offerings that Target Key Gaps Across the Medication Management Process at HIMSS18 194

Dec 04, 2017: BD Announces New Offerings to Help Customers Deliver Safer, Simpler and Smarter Medication Management 196

Nov 16, 2017: BD to Introduce Integrated Medication Management Platform Designed to Address Hospitals' Greatest Challenges at ASHP17 197

Apr 27, 2017: BD Advances Efforts to Combat Antimicrobial Resistance with Enhanced Diagnostic Solution Offering 198

Feb 20, 2017: BD Demonstrates Synchronized Technology Platform at HIMSS17 199

Other Significant Developments 200

Mar 22, 2018: BD Updates Instructions for Use for Certain BD Vacutainer Blood Collection Tubes 200

Feb 14, 2018: Attivo Networks Receives Validation for Attivo BOTsink Deception-Based Threat Detection through BD Product Security Partnership Program 201

Feb 01, 2018: BD Launches New Los Angeles County Program to Equip Patients with Essential Resources for Safe Sharps Disposal 202

Aug 24, 2017: BD Helps Thun Hospital Advance Medication Management Into the Future 203

Jul 18, 2017: BD Transforms Microbiology Urine Testing 205

May 09, 2017: BD and UniteOR to develop new surgical tray management solution 206

Feb 13, 2017: BD Announces Early Access Program for BD Resolve Single-Cell Analysis Platform 207

Appendix 208

Methodology 208

About GlobalData 208

Contact Us 208

Disclaimer 208


List of Figure

List of Figures

Becton Dickinson and Co, Medical Equipment, Deals by Type, 2012 to YTD 2018 2

Becton Dickinson and Co, Medical Equipment, Deals By Year, 2012 to YTD 2018 2

Becton Dickinson and Co, Medical Equipment, Deals By Region, 2012 to YTD 2018 2

Becton Dickinson and Co, Medical Equipment, Deals By Market, 2012 to YTD 2018 2

Becton Dickinson and Co, Medical Equipment, Deals By Year, 2012 to YTD 2018 10

Becton Dickinson and Co, Medical Equipment, Deals by Type, 2012 to YTD 2018 11

Becton Dickinson and Co, Medical Equipment, Deals By Region, 2012 to YTD 2018 12

Becton Dickinson and Co, Medical Equipment, Deals by Market, 2012 to YTD 2018 13


List of Table

List of Tables

Becton Dickinson and Co, Medical Equipment, Key Facts, 2017 2

Becton Dickinson and Co, Medical Equipment, Deals Summary, 2012 to YTD 2018 2

Becton Dickinson and Co, Medical Equipment, Deals By Year, 2012 to YTD 2018 10

Becton Dickinson and Co, Medical Equipment Deals By Type, 2012 to YTD 2018 11

Becton Dickinson and Co, Medical Equipment, Deals By Region, 2012 to YTD 2018 12

Becton Dickinson and Co, Deals By Market, 2012 to YTD 2018 13

Becton Dickinson and Co, Medical Equipment, Deals Summary, 2012 to YTD 2018 15

Becton, Dickinson Rumored to Sell Respiratory Devices Business 21

C. R. Bard Acquires Technology from 3DT Holdings 22

MeMed Raises USD70 Million in Financing Round 23

Medaware Raises USD8 Million in Series A Financing 25

TVA Medical Raises USD15 Million in Series C Financing 26

Embo Medical Raises USD3.7 Million in Seed Funding 27

Vascular Pathways Secures USD5 Million from Square 1 Bank 28

Vascular Pathways Raises USD5.5 Million in Venture Financing 29

TVA Medical Raises USD 9.5 Million In Series B Venture Financing 30

GenCell Biosystems Raises USD 3.5 Million In Seed Financing Round 31

Apax Partners to Acquire Remaining Minority Stake in Vyaire Medical for USD435 Million 32

UK Medical's Managment Acquires Company from Becton Dickinson 33

CareFusion Reportedly Elicits Acquisition Interest From Private Equity Firms 34

Roche Enters into Licensing Agreement with Becton Dickinson 35

Vancive Medical Enters Into Licensing Agreement With CareFusion For Antimicrobial Dressing 36

Asuragen Enters Into Licensing Agreement With Becton, Dickinson 37

SDIX Enters Into Licensing Agreement With BD Diagnostic 38

Noble Enters into Agreement with Becton Dickinson 39

Becton Dickinson and UniteOR Enter into Agreement 40

Becton, Dickinson Enters into Research Agreement with Juvenile Diabetes Research Foundation 41

Becton, Dickinson Forms Joint Venture with Apax Partners 42

Becton Dickinson and Singapore Immunology Network Enter into Research Agreement 43

Becton, Dickinson Enters into Distribution Agreement with Check-Points 44

Becton, Dickinson Enters into Co-Marketing Agreement with Sight Diagnostics 45

CareFusion Enters into Distribution Agreement with ResMed 46

CareFusion Enters into Distribution Agreement with AAM Healthcare 47

Edwards Lifesciences Enters into Agreement with CareFusion 48

Seegene Enters into Co-Development Agreement with BD Life Sciences 49

Becton, Dickinson Enters into Agreement with FlowJo 50

BD Life Sciences Enters into Co-Marketing with Cellular Research 51

Selah Genomics, Greenville Health, DecisionQ and Becton Dickinson Enter into Agreement 52

CareFusion Enters into Distribution Agreement with Breas Medical for Vivo Line of Ventilators 53

Boston Scientific Enters into Distribution Agreement with C. R. Bard for Lutonix DCB 54

Becton, Dickinson Enters into Agreement with Aethon to Develop Integrated Medication Management Solution 55

GenCell Biosystems To Enter Into Agreement With Fiocruz, Institute Of Molecular Biology Of Parana And Immunobiological Technology Institute To Develop Clinical Screening Systems 56

Terumo Enters Into Distribution Agreement With CareFusion For SurFlash Catheters In US 57

Becton, Dickinson Enters Into Collaboration Agreement With CME Medical For Saf-T-Intima Safety Integrated IV Catheter System 58

Juvenile Diabetes Research Extends Co-Development Agreement With Becton, Dickinson For Infusion And Glucose Monitoring Device 59

BD Diagnostics Amends Agreement With Bruker For BD Bruker Maldi Biotyper System 60

CytoVas And BD Biosciences Enter Into Co-Development Agreement For Vascular Health Diagnostics 61

Intelligent Hospital Systems Enters Into Technology Integration Agreement With Cato Software Solutions 62

BD Diagnostic Systems Enters Into Agreement With Lab21 To Develop New Oncology Assays 63

University of Limerick Enters Into Co-Development Agreement With GenCell 64

Epistem Enters Into Distribution Agreement With Becton Dickinson For Mycobacterium TB Test 65

Juvenile Diabetes Research Foundation Extends Co-Development Agreement With Becton, Dickinson 66

CareFusion Extends Distribution Agreement With Fisher & Paykel Healthcare 67

Becton, Dickinson Enters into Licensing Agreement with DiabetOmics 68

Becton Dickinson Raises USD2.47 Billion in Public Offering of Depositary Shares 69

Becton Dickinson Raises USD2.47 Billion in Public Offering of Shares 71

Becton, Dickinson Files Registration Statement For Public Offering Of Securities 73

Becton, Dickinson Raises USD374 Million in Public offering of 0.368% Notes Due 2019 74

Becton Dickinson Raises USD337.4 Million in Public Offering of 3.02% Notes Due 2025 75

Becton Dickinson Raises USD354.4 Million in Public Offering of 1.401% Notes Due 2023 76

Becton, Dickinson Raises USD 826.05 Million in Public Offering of 0.368% Notes Due 2019 77

Becton, Dickinson Raises USD2.4 Billion in Public Offering of 3.7% Notes Due 2027 78

Becton, Dickinson to Raise USD1 Billion in Public Offering of 2.404% Notes Due 2020 79

Becton, Dickinson to Raise USD1.75 Billion in Public Offering of 3.363% Notes Due 2024 80

Becton, Dickinson to Raise USD725 Million in Public Offering of 2.133% Notes Due 2019 81

Becton, Dickinson to Raise USD1.5 Billion in Public Offering of 4.669% Notes Due 2047 82

Becton, Dickinson to Raise USD500 Million in Public Offering of Floating Rate Notes Due 2022 83

Becton, Dickinson to Raise USD1.8 Billion in Public Offering of 2.894% Notes Due 2022 84

Becton Dickinson Prices Public Offering of 1% Notes Due 2022 for USD500 Million 85

Becton Dickinson Prices Public Offering of 1.9% Notes Due 2026 for USD500 Million 87

C. R. Bard Raises USD500 Million in Public Offering of 3% Notes Due 2026 89

Becton, Dickinson Raises USD1.2 Billion in Public Offering of 4.685% Notes Due 2044 90

Becton, Dickinson Raises USD1.75 Billion in Public Offering of 3.734% Notes Due 2024 92

Becton, Dickinson Raises USD750 Million in Public Offering of Floating Rate Notes Due 2016 94

Becton, Dickinson Raises USD1.25 Billion in Public Offering of 1.8% Notes Due 2017 96

Becton, Dickinson Raises USD1.25 Billion in Public Offering of 2.675% Notes Due 2019 98

CareFusion Raises USD300 Million in Public Offering of Notes Due 2044 100

CareFusion Raises USD300 Million in Private Placement of Notes Due 2017 101

CareFusion Raises USD400 Million in Public Offering of Notes Due 2024 103

CareFusion Completes Private Placement Of Notes Due 2023 For USD 300 Million 104

C. R. Bard Raises USD500 Million in Public Offering of 1.375% Notes Due 2018 105

Thermo Fisher Scientific to Acquire Advanced Bioprocessing Business from Becton, Dickinson and Company 106

Merit Medical Acquires Product Line from Becton, Dickinson for USD100 Million 107

Stryker Acquires Vertebral Augmentation Solutions Business from Becton, Dickinson 109

Fresenius Kabi USA Acquires US Pharma Plant and Ready to Administer Drugs from Becton, Dickinson 110

Becton, Dickinson May Divest Surgical Instruments Unit 111

Corning Completes Acquisition of Majority Stake In Discovery Labware Unit Of Becton, Dickinson For USD 730 Million 112

Natus Medical Completes Acquisition Of Nicolet Business From CareFusion For USD 58 Million 114

Becton Dickinson Acquires TVA Medical 116

Vyaire Medical Acquires Acutronic Medical Systems 117

Becton, Dickinson Acquires C. R. Bard for USD24 Billion 118

Becton, Dickinson Acquires Remaining 60% Stake in Caesarea Medical Electronics 120

C. R. Bard Acquires Liberator Medical for USD181 Million 121

C. R. Bard Acquires Embo Medical 123

C. R. Bard Acquires 50% Joint Venture Interest in Medicon from Kobayashi Pharma 124

Becton, Dickinson Acquires Cellular Research 125

C. R. Bard Acquires Vascular Pathways from MVM Life Science Partners 126

C. R. Bard Acquires Vascular Pathways Europe from MVM Life Science Partners 127

Becton, Dickinson Acquires CareFusion for USD12.2 Billion 128

BD Acquires CRISI Medical Systems 130

Becton, Dickinson Acquires GenCell Biosystems 131

Becton, Dickinson Acquires Alverix From Safeguard Scientifics And New Venture Partners For USD 40 Million 132

CareFusion Completes Partial Acquisition Of Vital Signs From GE Healthcare For USD 470 Million 134

C. R. Bard Completes Acquisition Of Rochester Medical For USD 262 Million 135

Boston Scientific Completes Acquisition of Bard Electrophysiology From C. R. Bard For USD 275 Million 136

CareFusion Acquires Stake In Sendal From GED Capital 138

Davol Completes Acquisition Of Medafor 139

C. R. Bard Acquires Loma Vista Medical 140

Becton, Dickinson Acquires Cato Software Solutions, Maker Of Medical Software Solutions 141

Becton, Dickinson Completes Acquisition Of Safety Syringes, Developer Of Anti-Needlestick Devices 142

Carefusion Completes Acquisition Of Intermed Equipamento Medico Hospitalar, Respiratory Device Company 143

C. R. Bard Acquires Neomend, Developer Of Wound Healing Products, For Up To USD 165 Million 144

Becton, Dickinson Acquires Sirigen, Developer Of Polymer Dyes 146

CareFusion Acquires UK Medical, Distributor Of Medical Products 148

Becton, Dickinson Acquires KIESTRA, Provider Of Lab Automation Solutions 149

Becton Dickinson and Co, Key Competitors 150

Becton Dickinson and Co, Key Employees 151

Becton Dickinson and Co, Other Locations 153

Becton Dickinson and Co, Subsidiaries 154

You can also purchase parts of this report.
Do you want to check out a section wise price list?
Get Price Break-up

Why Buy From US?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

reach
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022